Meliha C Kapetanovic

Medicine & Life Sciences

1. Rheumatoid Arthritis 100%
2. Pneumococcal Vaccines 69%
3. Conjugate Vaccines 68%
4. Vaccination 61%
5. Arthritis 41%
6. Antibody Formation 40%
7. Antirheumatic Agents 40%
8. Tumor Necrosis Factor Inhibitors 36%
9. Methotrexate 35%
10. Gout 35%
11. Sweden 32%
12. Rheumatic Diseases 29%
13. Rituximab 21%
14. Spondylarthropathies 20%
15. Infliximab 19%
16. Etanercept 19%
17. Antibodies 19%
18. Abatacept 18%
19. Serogroup 17%
20. Pneumococcal Infections 17%
21. Therapeutics 15%
22. 13-valent pneumococcal vaccine 15%
23. Vaccines 14%
24. Ankylosing Spondylitis 13%
25. Cohort Studies 12%
26. Immunization 12%
27. Comorbidity 11%
28. Observational Studies 11%
29. Prednisolone 10%
30. Heptavalent Pneumococcal Conjugate Vaccine 10%
31. tocilizumab 10%
32. Pharmaceutical Preparations 9%
33. Confidence Intervals 9%
34. Joint Diseases 9%
35. Joints 9%
36. Immunoglobulins 9%
37. 23-valent pneumococcal capsular polysaccharide vaccine 8%
38. Cartilage Oligomeric Matrix Protein 8%
39. Tumor Necrosis Factor-alpha 8%
40. Incidence 8%
41. Immunoglobulin G 7%
42. Infections 7%
43. Treatment Adherence and Compliance 7%
44. belimumab 7%
45. Biological Products 7%
46. Smoking 7%
47. Crystal Arthropathies 7%
48. Adalimumab 6%
49. B-Lymphocytes 6%
50. Cardiovascular Diseases 6%